![]() | |
Company type | Private |
---|---|
Industry | pharmaceutical industry |
Founded | Hayward, California, United States (1995 ) |
Headquarters | , United States |
Key people |
|
Products | Medici Drug Delivery System |
Website |
intarcia |
Intarcia Therapeutics is an American biopharmaceutical company based in Boston, MA and incorporated under the laws of Delaware. [1] [2] It was founded in 1995 under the name "BioMedicines" and changed to its present name in 2004. [1] In 2013, Intarcia relocated its headquarters to Boston, keeping its manufacturing facility in Hayward, CA. In addition to Boston and Hayward, Intarcia also has a location in Research Triangle Park, North Carolina, where it discovers and develops peptides for its drug delivery system. [3]
In 2005, the executive leadership of Intarcia was largely vested in two people, Karling Leung and James Ahlers, President/CEO/Director and Vice President/CFO/Finance & Operations Officer, respectively. [4] By 2012, Kurt Graves had replaced Karling Leung as President and CEO. [5] Kurt Graves has been with Intarcia since August 2010, first serving as Executive Chairman before becoming President and CEO in April 2012. [6]
As of 2016 [update], Intarcia is engaged in development of a "potential once-a-year type 2 diabetes treatment". Referred to as ITCA 650, the therapeutic consists of exenatide delivered via its Medici Drug Delivery System, [7] "a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides". [1] The drug was rejected for FDA approval in 2017 and 2020. [8]
In November 2012, Intarcia received $210M in preferred stock and debt financing from, The Baupost Group, Farallon Capital Management, New Enterprise Associates, New Leaf Venture Partners and Venrock Associates. [9] Other Investors include Greenspring Associates, [10] Alta Partners and Granite Venture Partners.
In April 2014, Intarcia secured an additional $200M in financing. RA Capital led the round and was joined by new and existing investors. [3] In April 2015, the company raised $225M in exchange for 1.5% of future global net sales of ITCA 650. [11] In May 2016, Intarcia secured an additional $75M in financing to scale-up manufacturing and inventory in anticipation of ITCA 650s global launch. [12] In September 2016, Intarcia raised an additional $215M in equity financing to prepare for the commercial launch of ITCA 650 in late 2017 and additional pipeline programs. [13]
![]() | |
Company type | Private |
---|---|
Industry | pharmaceutical industry |
Founded | Hayward, California, United States (1995 ) |
Headquarters | , United States |
Key people |
|
Products | Medici Drug Delivery System |
Website |
intarcia |
Intarcia Therapeutics is an American biopharmaceutical company based in Boston, MA and incorporated under the laws of Delaware. [1] [2] It was founded in 1995 under the name "BioMedicines" and changed to its present name in 2004. [1] In 2013, Intarcia relocated its headquarters to Boston, keeping its manufacturing facility in Hayward, CA. In addition to Boston and Hayward, Intarcia also has a location in Research Triangle Park, North Carolina, where it discovers and develops peptides for its drug delivery system. [3]
In 2005, the executive leadership of Intarcia was largely vested in two people, Karling Leung and James Ahlers, President/CEO/Director and Vice President/CFO/Finance & Operations Officer, respectively. [4] By 2012, Kurt Graves had replaced Karling Leung as President and CEO. [5] Kurt Graves has been with Intarcia since August 2010, first serving as Executive Chairman before becoming President and CEO in April 2012. [6]
As of 2016 [update], Intarcia is engaged in development of a "potential once-a-year type 2 diabetes treatment". Referred to as ITCA 650, the therapeutic consists of exenatide delivered via its Medici Drug Delivery System, [7] "a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides". [1] The drug was rejected for FDA approval in 2017 and 2020. [8]
In November 2012, Intarcia received $210M in preferred stock and debt financing from, The Baupost Group, Farallon Capital Management, New Enterprise Associates, New Leaf Venture Partners and Venrock Associates. [9] Other Investors include Greenspring Associates, [10] Alta Partners and Granite Venture Partners.
In April 2014, Intarcia secured an additional $200M in financing. RA Capital led the round and was joined by new and existing investors. [3] In April 2015, the company raised $225M in exchange for 1.5% of future global net sales of ITCA 650. [11] In May 2016, Intarcia secured an additional $75M in financing to scale-up manufacturing and inventory in anticipation of ITCA 650s global launch. [12] In September 2016, Intarcia raised an additional $215M in equity financing to prepare for the commercial launch of ITCA 650 in late 2017 and additional pipeline programs. [13]